212 related articles for article (PubMed ID: 36497049)
1. Efficacy of Clinically Used PARP Inhibitors in a Murine Model of Acute Lung Injury.
Martins V; Santos SS; Rodrigues LOCP; Salomao R; Liaudet L; Szabo C
Cells; 2022 Nov; 11(23):. PubMed ID: 36497049
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-Ribose) Polymerase Inhibition in Acute Lung Injury. A Reemerging Concept.
Szabo C; Martins V; Liaudet L
Am J Respir Cell Mol Biol; 2020 Nov; 63(5):571-590. PubMed ID: 32640172
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib, prevents acute lung injury associated cognitive deficits potentially through suppression of inflammatory response.
Sahu B; Narota A; Naura AS
Eur J Pharmacol; 2020 Jun; 877():173091. PubMed ID: 32234526
[TBL] [Abstract][Full Text] [Related]
4. The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis.
Ahmad A; Vieira JC; de Mello AH; de Lima TM; Ariga SK; Barbeiro DF; Barbeiro HV; Szczesny B; Törö G; Druzhyna N; Randi EB; Marcatti M; Toliver-Kinsky T; Kiss A; Liaudet L; Salomao R; Soriano FG; Szabo C
Pharmacol Res; 2019 Jul; 145():104263. PubMed ID: 31071432
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
6. Effects of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Cerulein-Induced Pancreatitis.
Ahmad A; Haas De Mello A; Szczesny B; Törö G; Marcatti M; Druzhyna N; Liaudet L; Tarantini S; Salomao R; Garcia Soriano F; Szabo C
Shock; 2020 May; 53(5):653-665. PubMed ID: 31274831
[TBL] [Abstract][Full Text] [Related]
7. The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.
Ahmad A; Olah G; Herndon DN; Szabo C
Br J Pharmacol; 2018 Jan; 175(2):232-245. PubMed ID: 28146604
[TBL] [Abstract][Full Text] [Related]
8. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
Ghonim MA; Pyakurel K; Ibba SV; Wang J; Rodriguez P; Al-Khami AA; Lammi MR; Kim H; Zea AH; Davis C; Okpechi S; Wyczechowska D; Al-Ghareeb K; Mansy MS; Ochoa A; Naura AS; Boulares AH
Clin Sci (Lond); 2015 Dec; 129(11):951-62. PubMed ID: 26205779
[TBL] [Abstract][Full Text] [Related]
9. Repurposing of Clinically Approved Poly-(ADP-Ribose) Polymerase Inhibitors for the Therapy of Sepsis.
Santos SS; Brunialti MKC; Soriano FG; Szabo C; Salomão R
Shock; 2021 Dec; 56(6):901-909. PubMed ID: 34115723
[TBL] [Abstract][Full Text] [Related]
10. PARP-1 inhibitor, DPQ, attenuates LPS-induced acute lung injury through inhibiting NF-κB-mediated inflammatory response.
Wang G; Huang X; Li Y; Guo K; Ning P; Zhang Y
PLoS One; 2013; 8(11):e79757. PubMed ID: 24278171
[TBL] [Abstract][Full Text] [Related]
11. PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice.
Dharwal V; Naura AS
Biochem Pharmacol; 2018 Apr; 150():24-34. PubMed ID: 29355504
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice.
Kapoor K; Singla E; Sahu B; Naura AS
Mol Cell Biochem; 2015 Feb; 400(1-2):153-62. PubMed ID: 25404465
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-Ribose) Polymerase 1 Promotes Inflammation and Fibrosis in a Mouse Model of Chronic Pancreatitis.
El-Hamoly T; Hajnády Z; Nagy-Pénzes M; Bakondi E; Regdon Z; Demény MA; Kovács K; Hegedűs C; Abd El-Rahman SS; Szabó É; Maléth J; Hegyi P; Virág L
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808340
[TBL] [Abstract][Full Text] [Related]
14. PolyADP-Ribosylation of NFATc3 and NF-κB Transcription Factors Modulate Macrophage Inflammatory Gene Expression in LPS-Induced Acute Lung Injury.
Nie Y; Nirujogi TS; Ranjan R; Reader BF; Chung S; Ballinger MN; Englert JA; Christman JW; Karpurapu M
J Innate Immun; 2021; 13(2):83-93. PubMed ID: 33045713
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib ameliorates influenza-virus-induced pneumonia in mice.
Liu W; Ren X; Wang Q; Zhang Y; Du J
Eur J Clin Microbiol Infect Dis; 2021 Jan; 40(1):159-167. PubMed ID: 32865668
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Mukhopadhyay P; Horváth B; Rajesh M; Varga ZV; Gariani K; Ryu D; Cao Z; Holovac E; Park O; Zhou Z; Xu MJ; Wang W; Godlewski G; Paloczi J; Nemeth BT; Persidsky Y; Liaudet L; Haskó G; Bai P; Boulares AH; Auwerx J; Gao B; Pacher P
J Hepatol; 2017 Mar; 66(3):589-600. PubMed ID: 27984176
[TBL] [Abstract][Full Text] [Related]
18. Protective Functions of PJ34, a Poly(ADP-ribose) Polymerase Inhibitor, Are Related to Down-Regulation of Calpain and Nuclear Factor-κB in a Mouse Model of Traumatic Brain Injury.
Tao X; Chen X; Hou Z; Hao S; Liu B
World Neurosurg; 2017 Nov; 107():888-899. PubMed ID: 28642177
[TBL] [Abstract][Full Text] [Related]
19. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
20. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer.
Lai SW; Bamodu OA; Chen JH; Wu AT; Lee WH; Chao TY; Yeh CT
Cells; 2020 Apr; 9(4):. PubMed ID: 32276472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
